Skip to main content
Pakistan Journal of Medical Sciences logoLink to Pakistan Journal of Medical Sciences
. 2015 Jan-Feb;31(1):198–202. doi: 10.12669/pjms.311.5997

Investigation on the IL-18 -607A/C and -137C/G on the susceptibility of ischemic stroke

Jin-he Shi 1, Li-dan Niu 2, Xi-yan Chen 3, Jing-yu Hou 4, Ping Yang 5, Guang-peng Li 6
PMCID: PMC4386186  PMID: 25878643

Abstract

Objective:

We conducted a case-control study with 322 cases and 322 controls to assess the role of the two common SNPs in the promoter of IL-18 gene.

Methods:

Polymerase chain reaction restriction fragment length of polymorphism (PCR-RFLP) was taken to genotype -607A/C and -137C/G in the promoter of the IL-18 gene.

Results:

By comparing cases and control subjects, we found that IS cases were more likely to have higher BMI, higher proportion of hypertension, and have higher proportion of smokers and drinkers. We found that IL-18 -607CC genotype (OR=1.70, 95% CI=1.03-2.81) and C allele (OR=1.26, 95% CI=1.01-1.58) were significantly more frequent in IS patients when compared with AA genotype. We did not find significant association between IL-18 -607A/C gene polymorphism and BMI, hypertension, smoking and drinking on the risk of IS.

Conclusion:

Our study suggests that polymorphisms in IL-18 -607A/C can influence the development of IS, and this gene polymorphism is associated with risk of IS in a Chinese population.

Key Words: IL-18, Ischemic stroke, Polymorphism

INTRODUCTION

Stroke is a leading cause of death, and this disease causes long-term disability in the world. Stroke causes a great burden for patients and their families because of lack of illustrated etiology and effective treatments.1 It is estimated that more than 80% of the stroke cases are ischemic stroke (IS) in origin. It is well known that IS is a mutifactorial disease with many environmental and genetic factors. Environmental factors such as hypertension, hyperlipidemia, smoking and drinking habits can increase the risk of IS, and many genetic factors also play an important role in the development of IS.2 Increasing evidences showed that inflammatory response have a role in the susceptibility to IS.3 Since inflammatory factors are one of the candidate genes for the risk of IS, the role of many inflammatory gene variations has been widely investigated in recent several years.

Several previous studies have shown that several certain polymorphisms in inflammatory genes have an important role in the development of IS, such as intereleukin-6 (IL-6), transforming growth factor (TGF-B1), interleukin-1 receptor antagonist(IL-1Ra), IL-1a and IL-1B and tumor necrosis factors as well as lymphotoxin-a.4-8 IL-18 is a member of the IL-1 superfamily, and this gene is a pleiotropic pro-inflammatory cytokine and has a role in the inflammatory cascade.9 Two previous studies have reported that higher level of IL-18 is associated with increased risk of IS.10,11

It is reported that the IL-18 gene is located on the region of chromosome 11q22.2-q23.3.12,13 There were two common gene polymorphisms, -607A/C(rs1946518) and -137C/G(rs187238), in the promoter of IL-18 gene. Previous studies have shown that C allele of IL-18-607A/C and G allele of IL-18-137C/G could affect the IL-18 higher transcription and its protein production.14,15 Previous studies have also shown that IL-18 gene polymorphisms are correlated with risk of cardiovascular disease.16,17 However, few studies have reported the association between IL-18 polymorphisms and risk of IS.

In order to assess the role of the two common SNPs of the promoter of IL-18 gene in the risk of IS, we conducted a case-control study with 322 cases and 322 controls in a Chinese population.

METHODS

Subjects: Our study included 322 patients who were first onset of IS, and all the patients with IS were selected from the First Affiliated Hospital of Xinxiang Medical University between January 2011 and January 2013. The diagnosis of IS was based on the clinical, cardiac, ultrasound and brain Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) tests. The diagnosis criteria was according to World Health Organization, and that is rapidly development of clinical signs of focal or global disturbance of cerebral function lasting>24 hours with no apparent cause but vascular origin. Cases who had type 2 diabetes, transient ischemic attacks, intracranial hemorrhage, congestive heart failure, postseizure palsy and brain tumor as well as asthma were excluded from this study.

The controls were frequency-matched with cases by age and sex. 322 control subjects were collected from the heath check-up center of the First Affiliated Hospital of Xinxiang Medical University, who came to our hospital for regular health check-up. An informed consent was obtained from all participants before enrolling into our study. The protocol of this study was approved by the First Affiliated Hospital of Xinxiang Medical University.

The age, sex, Body Mass Index (BMI), smoking and drinking habits, hypertension and diabetes were collected by a self-designed questionnaire. The BMI was calculated by weight divided by height squared. Hypertension was assessed according to hypertension guidelines from World Health Organization.

Genotyping assays: A 5mL sample of venous blood was collected from each IS case and control subject after enrolling into our study. The blood samples were kept at -20C until use, and EDTA 0.5 mg/ml was used to be anticoagulant for blood samples. Genomic DNA was extracted from the whole blood using a TIANamp blood DNA kit (Tiangen Biotech, Beijing, China) according to manufacturer’ instructions.

Polymerase chain reaction restriction fragment length of polymorphism (PCR-RFLP) was taken to genotype -607A/C and -137C/G in the promoter of the IL-18 gene. The PCR primers of IL-18 -607A/C & -137C/G were designed using primer 5.0 software according to the manufacturer’ instructions. Primers for -607A/C were 5’-GTTGCAGAAAGTGTAAAAATTATTAC-3’ (Forwards) and 5’-GTTGCAGAAAGTGTAAAAATTATTAA-3’ (Reverse), and primers for -137C/G were 5’-CCCCAACTTTTACGGAAGAAAAG-3’ and 5'- CCCCAACTTTTACGGAAGAAAAC-3’.

Amplification was conducted using the following processes: beginning with an initial denaturation for 5 minutes at 95°C, followed by 35 step cycles of denaturation at 95°C for 30s, annealing at 62°C for 30s, and extension at 72°C for 30s, and a final extension was taken at 72°C for 10 minutes. PCR products of IL-18 gene were assessed by 1.0% agarose gel electrophoresis and ultraviolet light. In order to perform quality control, we randomly selected 5% of IS cases and controls to repeat genotype, and we found the reproducibility was 100%.

Statistical Analysis: Continuous variables were shown as mean ± SD, and categorical variables were shown as frequencies and percentage (%). The continuous and categorical variables between cases and controls were compared by the χ2-test or student t test. A χ2-test was taken to assess the Hardy–Weinberg equilibrium of genotype distributions of control group. After adjusting potential risk factors of IS, a multivariate logistic regression analysis was performed to compare the genotype distributions of -607A/C and -137C/G in the promoter of the IL-18 gene between case and control groups. The results were expressed by an odds ratio (OR) and 95% confidence interval (95% CI). The homozygous genotypes of IL-18 -607A/C and -137C/G genotypes were used to be reference group. Two-sided P-values were taken to use in our study and a P-value<0.05 was defined as statistically significant. All statistical analyses were performed using STATA 9.0 software.

RESULTS

The demographic and lifestyle characteristics of IS patients and control subjects were shown in Table-I. There was no significant difference in terms of sex and age between cases and controls. By comparing characteristics between IS cases and control subjects, we found that IS cases were more likely to have higher BMI, higher frequency of hypertension, and have higher frequency of smokers and drinkers than control subjects.

Table-I.

Distributions of the demographic & lifestyle characteristics

Characteristics Cases % Controls % t or χ 2 p value
Age, years
Mean +SD, years 62.4±9.3 61.8±10.6
<60 149 46.27 170 52.80
≥60 173 53.73 152 47.20 2.74 0.10
Sex
Male 204 63.35 204 63.35
Female 118 36.65 118 36.65 0.00 1.00
BMI(kg/m2)
<25 207 64.29 233 72.36
≥25 115 35.71 89 27.64 4.85 0.03
Diabetes
No 73 22.67 59 18.32
Yes 249 77.33 263 81.68 1.87 0.17
Hypertension
No 181 56.21 82 25.47
Yes 141 43.79 240 74.53 62.99 <0.001
Smoking
Non-smoker 92 28.57 56 17.39
Current or ex-smoker 230 71.43 266 82.61 1.9 <0.001
Drinking
No 105 32.61 133 41.30
Yes 217 67.39 189 58.70 5.23 0.02

The genotype and allele frequencies of IL-18 -607A/C and -137C/G are shown in Table-II. The genotype and allele frequencies of the IL-18 -607A/C and -137C/G in controls did not deviate from Hardy-Weinberg equilibrium in the case and control groups. There was significant difference in the allele frequencies in terms of -607A/C between cases and controls (P<0.05) (Table-II).

Table-II.

Associated of IL-18 genotypes with risk of IS

IL-18 polymorphism Cases % Controls % p value OR(95%CI) 1
-607A/C genotype
AA 54 16.77 71 22.05 - 1.0(Ref.)
AC 180 55.9 183 56.83 0.22 1.29(0.84-1.99)
CC 88 27.33 68 21.12 0.03 1.70(1.03-2.81)
Allele
A 288 44.72 325 50.47 - 1.0(Ref.)
C 356 55.28 319 49.53 0.04 1.26(1.01-1.58)
-137C/G genotype
CC 11 3.42 18 5.59 - 1.0(Ref.)
CG 81 25.16 84 26.09 0.27 1.58(0.66-3.94)
GG 230 71.43 220 68.32 0.17 1.71(0.75-4.10)
Allele
C 103 15.99 120 18.63 - 1.0(Ref.)
G 541 84.01 524 81.37 0.21 1.20(0.89-1.62)

1. Adjusted for sex, age, BMI, diabetes, hypertension, smoking and drinking

IL-18 -607CC genotype (OR=1.70, 95% CI=1.03-2.81) and C allele (OR=1.26, 95% CI=1.01-1.58) were significantly more frequent in IS patients when compared with AA genotype (Table-II). However, we did not find significant association of IL-18 -137C/G gene polymorphism with risk of IS.

We further investigated the association between IL-18 -607A/C gene polymorphism and BMI, hypertension, smoking and drinking on the risk of IS (Table-III). Stratified analysis showed that an increased risk of IS was associated with those carrying IL-18 -607AC+CC, even in those with higher BMI, hypertension, smoking and drinking habits. However, no statistical significant difference was found between them, and no significant interaction between IL-18 -607A/C gene polymorphism and BMI, hypertension, smoking and drinking on the risk of IS.

Table-III.

Association between IL-18 -607A/C gene polymorphism and demographic characteristics on the risk of IS.

Characteristics -607AA
-607AC+CC
OR(95%CI) 1 p value
Cases Control Cases Control
BMI(kg/m2)
<25 36 51 171 182 1.33(0.81-2.21) 0.24
≥25 18 20 97 69 1.56(0.72-3.38) 0.21
Hypertension
No 31 22 150 60 1.77(0.90-3.45) 0.07
Yes 23 49 118 191 1.32(0.74-2.39) 0.32
Smoking
Non-smoker 13 11 79 45 1.49(0.55-3.92) 0.38
Current or ex-smoker 41 60 189 206 1.34(0.84-2.15) 0.19
Drinking
No 19 28 86 105 1.21(0.60-2.45) 0.56
Yes 35 43 182 146 1.53(0.90-2.60) 0.09

1. Adjusted for sex and age

DISCUSSION

The etiologies of IS are highly complicated and not well understood, and both environmental and genetic factors play a role in the development of IS, such as smoking, drinking, hypertension, diabetes and some genetic polymorphisms. Previous studies indicated that several certain polymorphisms in inflammatory genes can influence the risk of IS, such as intereleukin-6 (IL-6), transforming growth factor (TGF-B1), interleukin-1 receptor antagonist (IL-1Ra), IL-1a and IL-1B and tumor necrosis factors.4-8 The current study showed that IL-18 -607A/C polymorphisms can influence the risk of IS.

Genetic polymorphisms of cytokines can influence the expression or function of these cytokines, and polymorphisms in the genes can regulate the inflammatory mechanisms that play an important role in the pathology and development of IS. Previous study has shown that genetic polymorphisms of IL-18 -607A/C and -137C/G in the promoter IL-18 gene may affect the immune response, and can have a role in the risk of several kinds of diseases, such as tuberculosis, cancers, coronary artery disease and stroke.16,18-21

IL-18 -607A/C and -137C/G are located at the promoter of IL-18 gene, and previous studies have showed that the -607A allele and -137C allele are correlated with higher expression of IL-18.22,23 IL-18 has a role in causing spread and instability of atherosclerotic plaque, and previous studies have shown that IL-18 gene variations are associated with vascular changes in the carotid artery and associated with risk of coronary artery disease.16,24,25 Altering expression of IL-18 can cause the proliferation of human aortic smooth muscle cell, and thus induce the progress of atherosclerosis.26,27 Moreover, IL-18 is also involved in neuroinflammation in hypoxic-ischemic brain injuries.28 Only two previous clinical studies have shown that IL-18 gene polymorphisms are associated with development of IS.20,21 Zhang et al. investigated the association between IL-18 -607A/C and -137C/G and risk of ischemic stroke, and reported that -607C allele was associated with an increased risk of IS, and –137G allele was associated with increased risk of larger artery atheroscherosis.20 Lu et al. reported that IL-18-607C/A promoter polymorphism can influence the risk of IS, and C allele was correlated with an increased risk.21 The results of our study were in line with previous studies, our study reported that 607C allele was associated with increased risk of IS.

Several strengths can be considered in our study. First, the diagnosis of IS was used a rigorous method. The diagnosis of IS was based on the clinical, cardiac, ultrasound and brain Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) tests. Second, a relative larger sample size was taken in our study, which enhances the statistical power to find the difference between groups. Some limitations also should be considered in our study. First, our study is a case-control design, and thus a selection bias could not be avoided for the case and control groups. Second, this study might be applied only to our populations due to ethnicity differences. Third, other inflammatory gene polymorphisms may have a role in the development of IS, and may have interaction with IL-18 gene polymorphisms. Therefore, further large sample studies with more ethnicities are needed.

In conclusion, our study suggests that polymorphisms in IL-18 -607A/C can influence the development of IS, and this gene polymorphism is associated with risk of IS in a Chinese population. Our study supports the hypothesis that IL-18 gene polymorphism is associated with risk of IS, which suggests that further therapeutic studies should be conducted to reduce the activity of IL-18 to prevent the risk of IS.

Author’s Contributions:

JHS: Conceived, designed and did statistical analysis & editing of manuscript.

LDN, XYC, JYH, PY & GPL: Did data collection and manuscript writing.

References

  • 1.Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S. Heart disease & stroke statistics–2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–e215. doi: 10.1161/CIRCULATIONAHA.109.192667. doi: 10.1161/CIRCULATIONAHA.109.192667. [DOI] [PubMed] [Google Scholar]
  • 2.Dichgans M. Genetics of ischaemic stroke. Lancet Neurol. 2007;6(2):149–161. doi: 10.1016/S1474-4422(07)70028-5. doi:10.1016/S1474-4422(07)70028-5. [DOI] [PubMed] [Google Scholar]
  • 3.Lindsberg PJ, Grau AJ. Inflammation & infections as risk factors for ischemic stroke. Stroke. 2003;34(10):2518–2532. doi: 10.1161/01.STR.0000089015.51603.CC. doi: 10.1161/01.STR.0000089015.51603.CC. [DOI] [PubMed] [Google Scholar]
  • 4.Banerjee I, Gupta V, Ahmed T, Faizaan M, Agarwal P, Ganesh S. Inflammatory system gene polymorphism & the risk of stroke: a case-control study in an Indian population. Brain Res Bull. 2008;75(1):158–165. doi: 10.1016/j.brainresbull.2007.08.007. doi: 10.1016/j.brainresbull.2007.08.007. [DOI] [PubMed] [Google Scholar]
  • 5.Bis JC, Heckbert SR, Smith NL, Reiner AP, Rice K, Lumley T, et al. Variation in inflammation-related genes & risk of incident nonfatal myocardial infarction or ischemic stroke. Atherosclerosis. 2008;198(1):166–173. doi: 10.1016/j.atherosclerosis.2007.09.031. doi: 10.1016/j.atherosclerosis.2007.09.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kim Y, Lee C. The gene encoding transforming growth factor beta 1 confers risk of ischemic stroke & vascular dementia. Stroke. 2006;37(11):2843–2845. doi: 10.1161/01.STR.0000244782.76917.87. doi: 10.1161/01.STR.0000244782.76917. [DOI] [PubMed] [Google Scholar]
  • 7.Lee BC, Ahn SY, Doo HK, Yim SV, Lee HJ, Jin SY, et al. Susceptibility for ischemic stroke in Korean population is associated with polymorphisms of the interleukin-1 receptor antagonist and tumor necrosis factor-alpha genes, but not the interleukin-1beta gene. Neurosci Lett. 2004;357(1):33–36. doi: 10.1016/j.neulet.2003.12.041. doi: 10.1016/j.neulet.2003.12.041. [DOI] [PubMed] [Google Scholar]
  • 8.Li N, He Z, Xu J, Liu F, Deng S, Zhang H. Association of PDE4D & IL-1 gene polymorphism with ischemic stroke in a Han Chinese population. Brain Res Bull. 2010;81(1):38–42. doi: 10.1016/j.brainresbull.2009.09.009. doi: 10.1016/j.brainresbull.2009.09.009. [DOI] [PubMed] [Google Scholar]
  • 9.Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K. Interleukin-18: a novel cytokine that augments both innate & acquired immunity. Adv Immunol. 1998;70:281–312. doi: 10.1016/s0065-2776(08)60389-2. [DOI] [PubMed] [Google Scholar]
  • 10.Yuen CM, Chiu CA, Chang LT, Liou CW, Lu CH, Youssef AA, et al. Level & value of interleukin-18 after acute ischemic stroke. Circ J. 2007;71(11):1691–1696. doi: 10.1253/circj.71.1691. doi:10.1253/circj.71.1691. [DOI] [PubMed] [Google Scholar]
  • 11.Zaremba J, Losy J. Interleukin-18 in acute ischaemic stroke patients. Neurol Sci. 2003;24(3):117–124. doi: 10.1007/s10072-003-0096-0. [DOI] [PubMed] [Google Scholar]
  • 12.Koch W, Wolferstetter H, Schatke A, Schömig A, Kastrati A. Interleukin 18 gene variation and risk of acute myocardial infarction. Cytokine. 2011;56(3):786–791. doi: 10.1016/j.cyto.2011.09.006. [DOI] [PubMed] [Google Scholar]
  • 13.Kim HL, Cho SO, Kim SY, Kim SH, Chung WS, Chung SH, et al. Association of interleukin-18 gene polymorphism with body mass index in women. Reprod Biol Endocrinol. 2012;10 doi: 10.1186/1477-7827-10-31. doi:10.1186/1477-7827-10-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Giedraitis V, He B, Huang WX, Hillert J. Cloning & mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol. 2001;112(1–2):146–152. doi: 10.1016/s0165-5728(00)00407-0. [DOI] [PubMed] [Google Scholar]
  • 15.Bai J, Zhang Y, Lin M, Zeng X, Wang Z, Shen J. Interleukin-18 gene polymorphisms & haplotypes in patients with oral lichen planus: a study in an ethnic Chinese cohort. Tissue Antigens. 2007;70(5):390–397. doi: 10.1111/j.1399-0039.2007.00922.x. doi: 10.1111/j.1399-0039.2007.00922.x. [DOI] [PubMed] [Google Scholar]
  • 16.Opstad TB, Pettersen AA, Arnesen H, Seljeflot I. The co-existence of the IL-18+183 A/G and MMP-9 -1562 C/T polymorphisms is associated with clinical events in coronary artery disease patients. PLoS One. 2013;8(9) doi: 10.1371/journal.pone.0074498. doi: 10.1371/journal.pone.0074498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hernesniemi JA, Anttila K, Nieminen T, Kahonen M, Mononen N, Nikus K, et al. IL-18 gene polymorphism, cardiovascular mortality & coronary artery disease. Eur J Clin Invest. 2010;40(11):994–1001. doi: 10.1111/j.1365-2362.2010.02356.x. doi: 10.1111/j.1365-2362.2010.02356.x. [DOI] [PubMed] [Google Scholar]
  • 18.Tsai HT, Hsin CH, Hsieh YH, Tang CH, Yang SF, Lin CW, et al. Impact of interleukin-18 polymorphisms -607A/C & -137G/C on oral cancer occurrence & clinical progression. PLoS One. 2013;8(12) doi: 10.1371/journal.pone.0083572. doi: 10.1371/journal.pone.0083572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Yu XL, Zhao F, Zhang J, Pan XM. IL-18 genetic polymorphisms may contribute to the pathogenesis of tuberculosis among Asians: a meta-analysis of case-control studies. Mol Biol Rep. 2014 doi: 10.1007/s11033-014-3479-9. [Epub ahead of print] [DOI] [PubMed] [Google Scholar]
  • 20.Zhang N, Yu JT, Yu NN, Lu RC, Ma T, Wang ND, et al. Interleukin-18 promoter polymorphisms & risk of ischemic stroke. Brain Res Bull. 2010;81(6):590–594. doi: 10.1016/j.brainresbull.2010.01.008. doi: 10.1016/j.brainresbull.2010.01.008. [DOI] [PubMed] [Google Scholar]
  • 21.Lu JX, Lu ZQ, Zhang SL, Zhi J, Chen ZP, Wang WX. Correlation between interleukin-18 promoter -607C/A polymorphism & susceptibility to ischemic stroke. Braz J Med Biol Res. 2013;46(6):502–506. doi: 10.1590/1414-431X20132850. doi: 10.1590/1414-431X20132850. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Khripko OP, Sennikova NS, Lopatnikova JA, Khripko JI, Filipenko ML, Khrapov EA, et al. Association of single nucleotide polymorphisms in the IL-18 gene with production of IL-18 protein by mononuclear cells from healthy donors. Mediators Inflamm. 2008;2008 doi: 10.1155/2008/309721. doi: 10.1155/2008/309721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Giedraitis V, He B, Huang WX, Hillert J. Cloning & mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol. 2001;112(1-2):146–152. doi: 10.1016/s0165-5728(00)00407-0. [DOI] [PubMed] [Google Scholar]
  • 24.Rabkin SW. The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med. 2009;6(3):192–199. doi: 10.1038/ncpcardio1453. doi: 10.1038/ncpcardio1453. [DOI] [PubMed] [Google Scholar]
  • 25.Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res. 2002;90(2):E34–E38. doi: 10.1161/hh0202.105292. doi: 10.1161/hh0202.105292. [DOI] [PubMed] [Google Scholar]
  • 26.Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–874. doi: 10.1038/nature01323. [DOI] [PubMed] [Google Scholar]
  • 27.Liu W, Tang Q, Jiang H, Ding X, Liu Y, Zhu R, et al. Promoter polymorphism of interleukin-18 in angiographically proven coronary artery disease. Angiology. 2009;60(2):180–185. doi: 10.1177/0003319708319939. doi: 10.1177/0003319708319939. [DOI] [PubMed] [Google Scholar]
  • 28.Felderhoff-Mueser U, Schmidt OI, Oberholzer A, Bührer C, Stahel PF. IL-18: a key player in neuroinflammation & neurodegeneration? Trends Neurosci. 2005;28(9):487–493. doi: 10.1016/j.tins.2005.06.008. doi:10.1016/j.tins.2005.06.008. [DOI] [PubMed] [Google Scholar]

Articles from Pakistan Journal of Medical Sciences are provided here courtesy of Professional Medical Publications

RESOURCES